menu
    • menu
    [{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Torii Pharmaceutical \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Berotralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved","graph3":"Torii Pharmaceutical","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Torii Pharmaceutical","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Topical Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Torii Pharmaceutical","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Topical Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Berotralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved","graph3":"Torii Pharmaceutical","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Torii Pharmaceutical \/ Torii","highestDevelopmentStatusID":"12","companyTruncated":"Torii Pharmaceutical \/ Torii"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cantharidin","moa":"PP2A","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Nogra Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"NAC-GED-0507","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Torii Pharmaceutical \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Torii Pharmaceutical \/ Torii Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Torii Pharmaceutical

    Menu

    Torii Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Verrica Amends Collaboration with Torii to Fund Phase 3 Trial for YCANTH®

                            Details : Through the licensing agreement with Torii Pharmaceutical, to jointly conduct a global pivotal Phase 3 clinical trial studies of Ycanth (cantharidin) for the treatment of common warts.

                            Brand Name : Ycanth

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 15, 2024

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NAC-GED-0507

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Nogra Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Torii Has Entered Into a License Agreement with Nogra Pharma Limited to Develop & Commercialize NAC-GED-0507 i...

                            Details : Under the agreement, Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan for the treatment of acne vulgaris. NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of ...

                            Brand Name : NAC-GED-0507

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 26, 2023

                            Lead Product(s) : NAC-GED-0507

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Nogra Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum ...

                            Details : VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.

                            Brand Name : Ycanth

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 01, 2022

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : $15.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treat...

                            Details : Oral, once-daily ORLADEYO was approved in Japan in January 2021 for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

                            Brand Name : Orladeyo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 14, 2021

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : $15.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : $69.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical for VP-102

                            Details : Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted adm...

                            Brand Name : Ycanth

                            Molecule Type : Small molecule

                            Upfront Cash : $11.5 million

                            March 17, 2021

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : $69.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : $70.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102...

                            Details : The agreement grants Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.

                            Brand Name : VP-102

                            Molecule Type : Small molecule

                            Upfront Cash : $11.5 million

                            August 05, 2020

                            Lead Product(s) : Cantharidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Verrica Pharmaceuticals

                            Deal Size : $70.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : $42.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioCryst Submits Japanese NDA for Oral, Once Daily Berotralstat

                            Details : Torii Pharmaceutical will pay tiered royalties of up to 40 percent of Japanese net sales of berotralstat to BioCryst upon receipt of a reimbursement price approval NHI Japan.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $22.0 million

                            February 03, 2020

                            Lead Product(s) : Berotralstat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : $42.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Torii Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Delgocitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Japan Tobacco Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            JT to market CORECTIM in Japan to treat atopic dermatitis

                            Details : Under the terms of the agreement on October 2016nbetween JT and Torii, the drugs will be sold exclusively by Torii in Japan, following itsninclusion in the National Health Insurance (NHI) price list.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 15, 2020

                            Lead Product(s) : Delgocitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Japan Tobacco Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth